OCU400
- Generic Name
- OCU400
- Drug Type
- Biotech
- Background
OCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).
Expanded Access Program for RP in Adults
- Conditions
- Retinitis Pigmentosa
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Ocugen
- Registration Number
- NCT06574997
- Locations
- ๐บ๐ธ
Associated Retina Consultants, Phoenix, Arizona, United States
๐บ๐ธAdvanced Research, Deerfield Beach, Florida, United States
๐บ๐ธErie Retina Research, Erie, Pennsylvania, United States
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
Phase 1
Active, not recruiting
- Conditions
- Retinitis PigmentosaLeber Congenital Amaurosis
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 124
- Registration Number
- NCT05203939
- Locations
- ๐บ๐ธ
Associated Retina Consultants, Phoenix, Arizona, United States
๐บ๐ธOcugen Site 5 - University of California, San Diego (UCSD) - Shiley Eye Institute, La Jolla, California, United States
๐บ๐ธOcugen Site 3 - Bascom Palmer Eye Institute, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath